These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39306264)

  • 1. Cardiac contractility modulation in heart failure with reduced ejection fraction patients with QRS duration 120-149 ms: Reduction in heart failure hospitalizations and improvement in functional outcome.
    Fastner C; Varma N; Rao I; Falk P; Remppis BA; Najarian K; Burkhoff D; Akin I; Kuschyk J
    Heart Rhythm; 2024 Sep; ():. PubMed ID: 39306264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.
    Anker SD; Borggrefe M; Neuser H; Ohlow MA; Röger S; Goette A; Remppis BA; Kuck KH; Najarian KB; Gutterman DD; Rousso B; Burkhoff D; Hasenfuss G
    Eur J Heart Fail; 2019 Sep; 21(9):1103-1113. PubMed ID: 30652394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probability and magnitude of response to cardiac resynchronization therapy according to QRS duration and gender in nonischemic cardiomyopathy and LBBB.
    Varma N; Manne M; Nguyen D; He J; Niebauer M; Tchou P
    Heart Rhythm; 2014 Jul; 11(7):1139-47. PubMed ID: 24704570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study.
    Fastner C; Yuecel G; Hetjens S; Rudic B; Schmiel G; Toepel M; Liebe V; Kruska M; Borggrefe M; Burkhoff D; Akin I; Duerschmied D; Kuschyk J
    Clin Res Cardiol; 2022 Nov; 111(11):1286-1294. PubMed ID: 36056955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Device-therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy.
    Yuecel G; Gaasch L; Kodeih A; Hetjens S; Yazdani B; Pfleger S; Duerschmied D; Abraham WT; Akin I; Kuschyk J
    ESC Heart Fail; 2024 Sep; ():. PubMed ID: 39344273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-Specific Response to Cardiac Resynchronization Therapy: Effect of Left Ventricular Size and QRS Duration in Left Bundle Branch Block.
    Varma N; Lappe J; He J; Niebauer M; Manne M; Tchou P
    JACC Clin Electrophysiol; 2017 Aug; 3(8):844-853. PubMed ID: 29759781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
    Naser N
    Med Arch; 2022 Feb; 76(1):17-22. PubMed ID: 35422569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system.
    Kuschyk J; Falk P; Demming T; Marx O; Morley D; Rao I; Burkhoff D
    Eur J Heart Fail; 2021 Jul; 23(7):1160-1169. PubMed ID: 34002440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial.
    Varma N; Sogaard P; Bax JJ; Abraham WT; Borer JS; Dickstein K; Singh JP; Gras D; Holzmeister J; Brugada J; Ruschitzka F
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29807890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-Year Outcome of Cardiac Contractility Modulation in Patients With Reduced Ejection Fraction, Atrial Fibrillation, and Previous Resynchronization: A Pilot Study.
    Tint D; Micu S
    Am J Ther; 2023 Jan-Feb 01; 30(1):e10-e16. PubMed ID: 36367992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of left ventricular size with the outcome of cardiac resynchronization therapy in Japanese patients.
    Ito R; Kondo Y; Nakano M; Kajiyama T; Nakano M; Kitagawa M; Sugawara M; Chiba T; Kobayashi Y
    Clin Cardiol; 2024 Apr; 47(4):e24267. PubMed ID: 38619004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy.
    Braunschweig F; Linde C; Benson L; Ståhlberg M; Dahlström U; Lund LH
    Eur J Heart Fail; 2017 Mar; 19(3):366-376. PubMed ID: 27338764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac resynchronization therapy in patients with heart failure and narrow QRS complexes (≤ 130 ms): role of speckle tracking echocardiography and different interventricular (VV) pacing intervals.
    Kantharia BK; Singh A; Narasimhan B; Wu L; Karnik R; Chutani S; Shah AN
    J Interv Card Electrophysiol; 2022 Mar; 63(2):369-377. PubMed ID: 34138397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation.
    Abraham WT; Kuck KH; Goldsmith RL; Lindenfeld J; Reddy VY; Carson PE; Mann DL; Saville B; Parise H; Chan R; Wiegn P; Hastings JL; Kaplan AJ; Edelmann F; Luthje L; Kahwash R; Tomassoni GF; Gutterman DD; Stagg A; Burkhoff D; Hasenfuß G
    JACC Heart Fail; 2018 Oct; 6(10):874-883. PubMed ID: 29754812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure.
    Gijsberts CM; Benson L; Dahlström U; Sim D; Yeo DP; Ong HY; Jaufeerally F; Leong GK; Ling LH; Richards AM; de Kleijn DP; Lund LH; Lam CS
    Heart; 2016 Sep; 102(18):1464-71. PubMed ID: 27402805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine Learning of 12-Lead QRS Waveforms to Identify Cardiac Resynchronization Therapy Patients With Differential Outcomes.
    Feeny AK; Rickard J; Trulock KM; Patel D; Toro S; Moennich LA; Varma N; Niebauer MJ; Gorodeski EZ; Grimm RA; Barnard J; Madabhushi A; Chung MK
    Circ Arrhythm Electrophysiol; 2020 Jul; 13(7):e008210. PubMed ID: 32538136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≤130 ms: insights from a meta-analysis.
    Shah RM; Patel D; Molnar J; Ellenbogen KA; Koneru JN
    Europace; 2015 Feb; 17(2):267-73. PubMed ID: 25164431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome.
    Zweerink A; Friedman DJ; Klem I; van de Ven PM; Vink C; Biesbroek PS; Hansen SM; Emerek K; Kim RJ; van Rossum AC; Atwater BD; Nijveldt R; Allaart CP
    Circ Arrhythm Electrophysiol; 2018 Dec; 11(12):e006767. PubMed ID: 30541355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations.
    Zhang Q; Chan YS; Liang YJ; Fang F; Lam YY; Chan CP; Lee AP; Chan KC; Wu EB; Yu CM
    Int J Cardiol; 2013 Aug; 167(3):889-93. PubMed ID: 22330007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.